Skip to main content
All lobbying filings

ALPINE GROUP PARTNERS, LLC.

ALPINE GROUP PARTNERS, LLC. filed a Q3 report for CARL ZEISS, INC. on October 17, 2026, reporting $50,000 in lobbying income.

Lobbying for CARL ZEISS, INC. · Optics manufacturing company

All filings by ALPINE GROUP PARTNERS, LLC. · Everything CARL ZEISS, INC. has reported

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 20, 2026.
 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 17, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
New York

Official filing document

 Lobbyists on this filing 2
  • JENNIFER FORREST New on this filing
    Previously held: Executive Asst. Rep. Greg Walden
  • HANNAH SCHMIDT New on this filing
    Previously held: Professional Staff, House Small Business Cmte

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Science/Technology

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and IndustrialQuality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Trade (domestic/foreign)

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and IndustrialQuality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Manufacturing

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and IndustrialQuality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Waste (hazardous/solid/interstate/nuclear)

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and IndustrialQuality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Health Issues

Medical Technology, funding opportunities for biomedical research and export control policies; US Export Control Policy; Trade and tariff policy; Medical and IndustrialQuality & Research; Metrology/Microscopy Technology; PFAS regulations; Medical Technology, federal funding opportunities for biomedical research, MDUFA and vision care

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem